PARP inhibitor nanotherapy for ovarian cancer

被引：0

|

作者：

Baldwin, Paige ^{[1
]}

Ohman, Anders ^{[2
]}

Thong, Jeremy ^{[1
]}

Tangutoori, Shifalika ^{[1
]}

Dinulescu, Daniela ^{[2
]}

Sridhar, Srinivas ^{[1
]}

机构：

[1] Northeastern Univ, Boston, MA 02115 USA

[2] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA

来源：

CLINICAL CANCER RESEARCH | 2016年 / 22卷

关键词：

D O I：

10.1158/1557-3265.OVCA15-A03

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A03

引用

收藏

页数：2

相关论文

共 50 条

[1] Targeted nanotherapy using the PARP inhibitor talazoparib for breast cancer treatment
Baldwin, Paige
Kumar, Rajiv
Sridhar, Srinivas
[J]. CANCER RESEARCH, 2018, 78 (13)
[2] FDA approves PARP inhibitor for ovarian cancer
Waltz, Emily
[J]. NATURE BIOTECHNOLOGY, 2017, 35 (05) : 398 - 398
[3] PARP Inhibitor Treatment in Ovarian and Breast Cancer
不详
[J]. CURRENT PROBLEMS IN CANCER, 2011, 35 (01) : 7 - 50
[4] Overcoming PARP inhibitor resistance in ovarian cancer
Pina, Pamela Soberanis
Lheureux, Stephanie
[J]. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2023, 33 (03) : 364 - 376
[5] Perspectives on PARP Inhibitor Combinations for Ovarian Cancer
Bonadio, Renata Colombo
Estevez-Diz, Maria del Pilar
[J]. FRONTIERS IN ONCOLOGY, 2021, 11
[6] FDA approves PARP inhibitor for ovarian cancer
[J]. Nature Biotechnology, 2017, 35 : 398 - 398
[7] Mechanisms of PARP inhibitor resistance in ovarian cancer
Kubalanza, Kari
Konecny, Gottfried E.
[J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2020, 32 (01) : 36 - 41
[8] PARP Inhibitor Resistance and Acquired Vulnerability in Ovarian Cancer
D'Andrea, Alan
[J]. ONCOLOGIST, 2017, 22 : S1 - S1
[9] Identifying the radiosensitizing effects of PARP inhibitor in ovarian cancer
Bi, Yue
Verginadis, Ioannis
Dey, Souvik
Guo, Linlang
Lin, Lilie
Zheng, Yanfang
Koumenis, Constantinos
[J]. CANCER RESEARCH, 2017, 77
[10] PARP Inhibitor Treatment in Ovarian and Breast Cancer Foreword
Kummar, Shivaani
[J]. CURRENT PROBLEMS IN CANCER, 2011, 35 (01) : 6 - 6

← 1 2 3 4 5 →